Establishment and Epitope Mapping of Anti-Diacylglycerol Kinase α Monoclonal Antibody DaMab-8 for Immunohistochemical Analyses.

Establishment and Epitope Mapping of Anti-Diacylglycerol Kinase α Monoclonal Antibody DaMab-8 for Immunohistochemical Analyses. Monoclon Antib Immunodiagn Immunother. 2019 May 17;: Authors: Sano M, Kaneko MK, Suzuki H, Kato Y Abstract Diacylglycerol kinase (DGK) converts diacylglycerol (DG) into phosphatidic acid (PA). DGKα, 1 of the 10 DGK isozymes, is involved in T cell function. In the present study, we describe a specific monoclonal antibody DaMab-8 (mouse IgG1, kappa) against DGKα, which is extremely useful for performing immunohistochemical analysis for T cells in oropharyngeal squamous cell carcinomas. Furthermore, we characterized the binding epitope of DaMab-8 using Western blotting and found that the sites Asn610, Leu611, Trp612, Gly613, Asp614, His619, Tyr623, and Gly624 of DGKα are important for facilitating the DaMab-8 binding to the DGKα protein. Thus, DaMab-8 could be advantageous for immunohistochemical analyses toward clarifying the distribution of DGKα-expressing T cells in every pathophysiological tissue. PMID: 31099705 [PubMed - as supplied by publisher]
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research

Related Links:

PMID: 31690109 [PubMed - as supplied by publisher]
Source: Ear, Nose and Throat Journal - Category: ENT & OMF Authors: Tags: Ear Nose Throat J Source Type: research
ConclusionsOur results indicate that high abundance of TIL-Bs and high density of direct B cell/CD8+ T cell interactions can predict patients with excellent prognosis, who would benefit from less invasive treatment. We propose that in extensively infiltrated tumors, TIL-Bs might recruit CD8+ T cells via CXCL9 and due to a highly activated phenotype contribute by secondary costimulation to the maintenance of CD8+ T cells in the tumor microenvironment.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsThe analysis of HLA-ligandomes from OPSCC revealed tumor-exclusive and newly discovered antigens. We found clear differences between the HLA ligandomes of HPV+ and HPV- patients. These differences need to be taken into account for therapeutic vaccination strategies. The level of personalization needed for such vaccines remains to be determined.Legal entity responsible for the studyThe authors.FundingUniversity of Ulm, Clinician Scientist Programme.DisclosureS. Laban: Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Merck Sharp&Dohme (MSD); Honoraria (institution), Advisory ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsAdjuvant nivolumab after salvage surgery in HNSCC patients is safe however, increased enrollment is required to establish efficacy.Clinical trial identificationNCT03355560.Legal entity responsible for the studyTrisha Wise-Draper.FundingBMS.DisclosureT. Wise-Draper: Research grant / Funding (self): BMS; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Merck; Research grant / Funding (institution): Tesaro. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe substudy of mona in monotherapy did not meet its primary objective and was closed at interim for futility. Median PFS was 7.4 wks. Mona has a favorable safety profile and is under investigation in combination with durvalumab within the UPSTREAM trial.Clinical trial identificationNCT03088059.Legal entity responsible for the studyEORTC.FundingEORTC, Innate Pharma.DisclosureR. Galot: Advisory / Consultancy: Innate Pharma; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Astellas. C. Le Tourneau: Advisory / Consultancy: MSD; Advisory / Consultancy: Merck-Serono; Advisory / Consultancy...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractHead and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for over 10,000 annual deaths in the United States alone. Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and Drug Administration (FDA) granted the first immunotherapeutic approvals – the anti-PD-1 immune checkpoint inhibitors nivolumab and pembrolizumab – for the treatment of pa...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
ConclusionOur results indicate that serum TIMP-1 levels may serve as an independent prognostic marker for HPV-negative OPSCC patients.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Head and neck squamous cell carcinoma (HNSCC) originates from squamous epithelium of the upper aerodigestive tract and is the most common malignancy in the head and neck region. Among HNSCCs, oropharynx squamo...
Source: Journal of Translational Medicine - Category: Research Authors: Tags: Research Source Type: research
In this study, we performed immunohistochemical analysis using a rabbit anti-DGKζ monoclonal antibody (mAb) (clone EPR22040-80) against tissues from the tonsils of a patient with oropharyngeal squamous cell carcinoma. We demonstrated that many DGKζ-expressing T cells are localized in the tonsils. We further characterized the binding epitope using an enzyme-linked immunosorbent assay and found that Pro790, Gln791, Gly792, and Leu795 residues of DGKζ are important for facilitating anti-DGKζ mAb binding to DGKζ. This anti-DGKζ mAb could be valuable in immunohistochemical analyses in determining t...
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research
This article reviews the accumulated evidence on the role of cetuximab in HNSCC in the past decade, offering an overview of its current impact in the treatment of LA and R/M-HNSCC disease and its potential use in the era of immunotherapy.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Carcinoma | Immunotherapy | Microbiology | Oropharyngeal Cancer | Squamous Cell Carcinoma | Study